BioCentury
ARTICLE | Clinical News

BIOD-123: Phase II started

September 17, 2012 7:00 AM UTC

Biodel began an open-label, U.S. Phase II trial to compare BIOD-123 plus Lantus insulin glargine vs. insulin lispro plus Lantus for 18 weeks in 130 Type I diabetics. Sanofi (Euronext:SAN; NYSE:SNY, ...